Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ia trial of PSI 938 in patients with hepatitis C.

Next Previous
Trial Profile

Phase Ia trial of PSI 938 in patients with hepatitis C.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PSI 938 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Acronyms SAD
  • Sponsors Pharmasset

Most Recent Events

  • 07 Feb 2011 7- and 14-day results have been reported, according to a Pharmasset media release
  • 28 Oct 2010 Results will be presented at the American Association for the Study of Liver Diseases Annual Liver Meeting, according to a Pharmasset media release.
  • 28 Jul 2010 Preliminary results have been announced by Pharmasset in a media release. Further results are expected in the third quarter of 2010.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top